Eagle Biosciences Blog | EagleBio

The Eagle Biosciences Noradrenaline (Norepinephrine) Sensitive ELISA was used in a recent study. This highly sensitive assay kit is part of our veterinary and neurobiology product lines. It is intended for the detection of noradrenaline (norepinephrine) in biological samples including serum, plasma, tissue, and cell culture samples of mice and rats.

Renal Denervation and CD161a Immune Ablation Prevent Cholinergic Hypertension and Renal Sodium Retention

Abstract

Cholinergic receptor activation leads to premature development of hypertension and infiltration of pro-inflammatory CD161a+/CD68+ M1 macrophages into the renal medulla. Renal inflammation is implicated in renal sodium retention and the development of hypertension. Renal denervation is known to decrease renal inflammation. To determine the role of CD161a+/CD68+ macrophages and renal sympathetic nerves in cholinergic-hypertension & renal sodium retention. Bilateral renal denervation (RND) and immune ablation of CD161a+ immune cells was performed in young prehypertensive SHR followed by infusion of either saline or nicotine (15mg/kg/day) for two weeks. Immune ablation was conducted by injection of unconjugated azide-free antibody targeting rat CD161a. Blood pressure was monitored by tail cuff plethysmography. Tissues were harvested at the end of infusion. Nicotine induced premature hypertension, renal expression of the sodium-potassium-chloride co-transporter (NKCC2), increases in renal sodium retention, and infiltration of CD161a+/CD68+ macrophages into the renal medulla of animals. All of these effects were abrogated or prevented by RND and ablation of CD161a+ immune cells. Cholinergic activation of CD161a+ positive immune cells leads to the premature development of hypertension in SHR, at least partly, through increased renal expression of NKCC2 and renal sodium retention. Effects on chemotaxis of CD161a+ macrophages to the renal medulla, decreased renal expression of NKCC2, and renal sodium retention appear to play a part in the prevention of cholinergic hypertension as a result of RND. The CD161a+ immune cells are necessary and essential for this pro-hypertensive nicotine-mediated inflammatory response. Cholinergic receptor activation leads to premature development of hypertension and infiltration of pro-inflammatory CD161a+/CD68+ M1 macrophages into the renal medulla. Renal inflammation is implicated in renal sodium retention and the development of hypertension. Renal denervation is known to decrease renal inflammation. To determine the role of CD161a+/CD68+ macrophages and renal sympathetic nerves in cholinergic-hypertension and renal sodium retention. Bilateral renal denervation (RND) and immune ablation of CD161a+ immune cells was performed in young prehypertensive SHR followed by infusion of either saline or nicotine (15mg/kg/day) for two weeks. Immune ablation was conducted by injection of unconjugated azide-free antibody targeting rat CD161a. Blood pressure was monitored by tail cuff plethysmography. Tissues were harvested at the end of infusion. Nicotine induced premature hypertension, renal expression of the sodium-potassium-chloride co-transporter (NKCC2), increases in renal sodium retention, and infiltration of CD161a+/CD68+ macrophages into the renal medulla of animals. All of these effects were abrogated or prevented by RND and ablation of CD161a+ immune cells. Cholinergic activation of CD161a+ positive immune cells leads to the premature development of hypertension in SHR, at least partly, through increased renal expression of NKCC2 and renal sodium retention. Effects on chemotaxis of CD161a+ macrophages to the renal medulla, decreased renal expression of NKCC2, and renal sodium retention appear to play a part in the prevention of cholinergic hypertension as a result of RND. The CD161a+ immune cells are necessary and essential for this pro-hypertensive nicotine-mediated inflammatory response.

Raikwar, NS;Braverman, C;Snyder, PM;Fenton, RA;Meyerholz, DK;Abboud, FM;Harwani, SC; (2019). Renal Denervation and CD161a Immune Ablation Prevent Cholinergic Hypertension and Renal Sodium Retention. Am. J. Physiol. Heart Circ. Physiol.. doi:10.1152/ajpheart.00234.2019.

Biomarker Spotlight

Biomarker Spotlight: Noggin

by Eagle Biosciences

Noggin is a secreted homodimeric glycoprotein that is involved in the development of many body tissues, including nerve tissue, muscles, and bones. Noggin is crucial during embryogenesis and is involved in the regulation of several developmental processes, including neural tube formation, cardiomycyte growth, skeletal development, and joint formation. Noggin is highly conserved in vertebrates, and is found in certain areas of the central nervous system, lungs, skeletal muscles, and skin of adults.

Why is it important?

Research has shown that noggin plays a role in learning, cognition, bone development, and neural tube function, as well as nervous system, somite and skeletal development. A lack of noggin during embryo development can lead to stunted bone growth, missing skeletal elements, or failure to develop articulating joints. Mutations of the noggin gene can cause joint fusions, multiple synostosis, proximal symphalangism and other deformities or syndromes.

In adult patients, increased levels of noggin in plasma have been linked to obesity.

NOGGIN has also been linked to:
Bone Tumors
Ankylosing Spondylitis
Non Alcoholic Fatty Liver Disease (NAFLD)
Pulmonary Arterial Hypertension (PAH)

Eagle Biosciences offers a highly sensitive Metal Enhanced Direct Sandwich Fluorescence Immunoassay to test for Noggin.
FluoBolt-Noggin Fluorescence Immunoassay

Uncategorized

GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis

by Eagle Biosciences

GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis

Mayo Clinic

Meningoencephalomyelitis is swelling of the brain or spinal cord caused by an autoimmune reaction. Symptoms include headaches, progressive weakness, confusion and blurred vision. This condition can be treated with steroid therapy, but it is often misdiagnosed as meningitis, encephalitis, myelitis, or a variety of other conditions.

Researchers have developed a unique test to detect a novel form of the disease known as autoimmune glilial fibrillary acidic protein (GFAP) astrocytopathy. This test would be part of encephalitis and myelopathy evaluations. The recommended test involves a test of the patient’s spinal fluid, as well as a serum test.

Toman, Barbara J. “GFAP: Novel Test for a Newly Identified Meningoencephalomyelitis.” Mayo Clinic Laboratories, https://news.mayocliniclabs.com/2019/06/28/gfap/.

Eagle Biosciences offers the most sensitive assays available worldwide in simple-to-use ELISA and Chemiluminescence formats for detecting GFAP:

Biomarker Spotlight

Biomarker Spotlight: GFAP

by Eagle Biosciences

Glial Fibrillary Acidic Protein (GFAP) is a monomeric intermediate protein found in the astroglial cells of the Central Nervous System. Astroglial cells are found in the white and gray matter of the brain. GFAP and other intermediate filaments provide support and nourishment for cells in the brain and spinal cord.

Why is GFAP Important?

Astroglial cells produce GFAP when an injury or trauma damages the cells of the central nervous system. Glial Fibrillary Acidic Protein (GFAP) is a promising research brain-specific glial-derived biomarker for TBI (traumatic brain injury) in adults and children. Studies have demonstrated that GFAP is released into serum following a TBI within an hour of injury and remains elevated for several days after injury. All indications are the GFAP is an interesting biomarker for indication of a TBI and retinal stress.

Eagle Biosciences offers the most sensitive assays available worldwide in simple-to-use ELISA and Chemiluminescence formats for detecting GFAP:

Supplier Agreement Announcements

Eagle Welcomes StressMarq!

by Eagle Biosciences

Eagle Biosciences, Inc is excited to collaborate with Canadian biotech StressMarq as their U.S. distributor. With access to their extensive portfolio of over 7,000 items, this partnership enables us to offer a wide variety of cutting-edge products.

Their product catalog includes:
• Antibodies
• Antibody Conjugates
• Assay Kits
• Proteins
• Small Molecules
• And much more

About StressMarq

Stressmarq Biosciences Inc. is headquartered in Victoria, BC, Canada. They continually produce cutting edge research products that undergo rigorous quality controls to ensure their products meet the highest standards. Their mission statement is to provide “Discovery through partnership, and Excellence through quality.”

Eagle Biosciences has access to all of Stressmarqs’ products. Don’t see what you need online? Contact us for more information and we can get it for you!

Uncategorized

Functional Leptin ELISA Utilized in a Clinical Study

by Eagle Biosciences

Eagle Biosciences Functional Leptin ELISA Assay Kit was utilized in a clinical study to monitor those with functional leptin deficiency. Circulating leptin levels in the body are crucial for maintaining body weight. This clinical study was developed to test for a valid diagnostic tool to detect functionally leptin in those who have defective leptin receptor binding. To view more information about our Leptin ELISA Assay Kit click here.

Abstract:

Context and aims: Functional leptin deficiency is characterized by high levels of circulating immunoreactive leptin (irLep), but a reduced bioactivity of the hormone due to defective receptor binding. As a result of the fact that affected patients can be successfully treated with metreleptin, it was aimed to develop and validate a diagnostic tool to detect functional leptin deficiency.

Methods: An immunoassay capable of recognizing the functionally relevant receptor-binding complex with leptin was developed (bioLep). The analytical quality of bioLep was validated and compared to a conventional assay for immune-reactive leptin (irLep). Its clinical relevance was evaluated in a cohort of lean and obese children and adults as well as in children diagnosed with functional leptin deficiency and their parents.

Results: In the clinical cohort, a bioLep/irLep ratio of 1.07 (range: 0.80–1.41) was observed. Serum of patients with non-functional leptin due to homozygous amino acid exchanges (D100Y or N103K) revealed high irLep but non-detectable bioLep levels. Upon treatment of these patients with metreleptin, irLep levels decreased, whereas levels of bioLep increased continuously. In patient relatives with heterozygous amino acid exchanges, a bioLep/irLep ratio of 0.52 (range: 0.48–0.55) being distinct from normal was observed.

Conclusions: The new bioLep assay is able to diagnose impaired leptin bioactivity in severely obese patients with a homozygous gene defect and in heterozygous carriers of such mutations. The assay serves as a diagnostic tool to monitor leptin bioactivity during treatment of these patients.

Wabitsch, M., Pridzun, L., Ranke, M., Schnurbein, J. V., Moss, A., Brandt, S., . . . Kratzsch, J. (2017). Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency. European Journal of Endocrinology,176(3), 315-322. doi:10.1530/eje-16-0821

Biomarker Spotlight

Biomarker Spotlight: FGF-23

by Eagle Biosciences

FGF-23 is a hormone that is secreted by osteoblasts within the bones. This protein works with the kidneys to help regulated levels of phosphate in the blood/serum. The kidney gets rid of excess phosphate by excreting it in urine. When more phosphate is needed, the kidney reabsorb phosphate into the bloodstream. FGF-23 signals the kidneys to stop reabsorbing phosphate into the bloodstream. This fibroblastic growth factor binds to a receptor protein called FGF receptor 1. These receptors span the membrane of kidney cells. The binding of the protein and the receptors stimulates a signal cascade that stops phosphate reabsorption into the bloodstream.

image credit: https://www.kidney-international.org/

Why measure FGF-23?

Phosphate plays a critical role in the formation and growth of bones in children and for maintaining bone strength in adults. An imbalance in levels of FGF-23 in the body causes high or low levels of phosphate in the bloodstream. Low levels of phosphate in the blood can result in hypophosphatemia rickets or osteomalacia, which is a weakening of the bone which can cause bone pain and fractures. High levels of phosphate in the blood can indicate kidney disfunction.

Check out our two kits used for measuring FGF-23:

Uncategorized

Calretinin: A Potential Biomarker for Mesothelioma

by Eagle Biosciences

Mesothelioma is a malignant lung cancer that is commonly associated with previous asbestos exposure. Often it is not diagnosed until too late to treat in a patient. Calretinin has recently been in the spotlight as a potential biomarker for early detection of mesothelioma.

Two recent studies used Eagle Bioscience’s Calretinin ELISA Assay kit analyzing the accuracy of using Calretinin as a prediagnostic technique for mesothelioma:

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
Aguilar-Madrid, Guadalupe, et al. “Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population .” International Journal of Medical Sciences, vol. 15, no. 9, 2018, pp. 883–891.

Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
Johnen, G., Burek, K., Raiko, I., Wichert, K., Pesch, B., Weber, D. G., . . . Brüning, T. (2018). Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Scientific Reports,8(1).

Learn more about our Calretinin ELISA Assay kit here.

Uncategorized

Tradeshows and Conferences and Meetings, Oh My!

by Eagle Biosciences

2018 was a big year here at Eagle Biosciences, and 2019 is expected to be even better! We will be making appearances at many tradeshows and conferences this year!

Endo2019
March 23rd-26th
New Orleans, LA
Booth #1930

AACR Annual Meeting
March 29th-April 3rd
Atlanta, GA
Booth #4644

AACC Annual Meeting
August 4th-8th
Anaheim, CA
*Attending, but will not have a booth. Email us if you would like to set up a meeting time

The Association of Medical Laboratory Immunologists (AMLI) Annual Scientific Meeting
August 16th-19th
Cleveland, OH
Booth #8

American Society for Bone and Mineral Research (ASBMR) Annual Meeting
September 20th-23rd
Orlando, FL
Booth #626

ASN Kidney Week
November 5th-10th
Washington, DC
Booth #2005

Medica Tradefair
November 18th-21st
Düsseldorf, Germany

We’d love to meet you!

If you will be attending any of these events, stop by and say hi! Or set up a meeting if you have any big plans you’d like to talk about

Uncategorized

Eagle Welcomes Fianostics!

by Eagle Biosciences

Eagle Biosciences, Inc. is excited to collaborate with Austrian biotech Fianostics, to offer a new fluorescence-based detection platform for immunoassays, called FluoBolt™, which enables highly sensitive assays with high reproducibility and reliability. This dramatically improves the informative value of research with biomarkers.

So far, Fianostics FluoBolt™ Metal Enhanced Fluorescence Immunoassays have been developed to detect

Asporin
Noggin
Periostin
and many more to come!

What Makes These Assays Different?

Fianostics FluoBolt™ Metal Enhanced Fluorescence Immunoassays have been established to eliminate the complicated processes that come with your standard sandwich ELISA. By using their FluoBolt™ Metal Enhanced Fluorescence Immunoassays, you can expect

High Sensitivity!
Single Step Assay Procedure!
No Enzyme Substrate!
Stable Signal over Time!
100% Compatibility with 96-well ELISA Format!

About Fianostics

Fianostics combines scientific and technical expertise in diagnostics with the development of a high-tech detection platform that benefits in reproducibility from the excellent expertise of Sony DADC BioSciences in the production of polymer consumables for the diagnostic industry. Their know-how is not limited to the development of the new detection platform, but we also provide the diagnostic application with the appropriate immunoassays for specific clinical areas. (for research use only in the US)

About Metal Enhanced Fluorescence

Metal Enhanced Fluorescence (MEF) offers the possibility to dramatically increase the analytical sensitivity of systems based on fluorescence detection. MEF is based on the fact that excitation light interacts with the electrons of metal nano–structures thus generating very high electromagnetic fields (Localised Surface Plasmons, LSPs ) Therefore, such structures are also called

”plasmonic structures” and the combination of (e.g, polymeric) support and structure is known as “plasmonic substrate”. These LSPs lead to an increase in emission output of fluorescent molecules (e.g. fluorescently labelled antibodies) when bound to surfaces with suitable nano-metal structures that can enhance the signal more than 100 times.